藥明康德:預計未來不會被納入UVL名單
格隆匯2月9日丨今日藥明康德(603259.SH/2359.HK)就近期情況召開溝通交流會,公司方面表示業務和運營一切正常,藥明康德不在“未經覈實名單”(UVL)名單中,預計未來也不會被納入該名單。“我們所有的認證文件都是最新的,我們的供應商也一直與政府機構就相關審批保持良好的溝通。公司嚴格遵守美國相關的法律法規,也歡迎美國商務部和其他監管機構的監督,包括根據需要進行現場檢查。”注:受“兄弟公司”藥明生物(2269.HK)的兩家子公司被美國商務部列入UVL事件影響, 2月8日藥明康德A股和H股分別收跌9.99%和11.36%,今日分別收跌1.41%和4.17%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.